Search Results
Your search for early matches 10493 pages
Showing 1301 - 1350ALINA Trial: Anticancer Activity of Alectinib Reported in Earlier-Stage, ALK-Positive NSCLC
Treatment with the anaplastic lymphoma kinase (ALK) inhibitor alectinib significantly reduced the risk of recurrence or death by 76% (P < .0001) in patients with completely resected stage IB to IIIA ALK-positive non–small cell lung cancer (NSCLC) compared with platinum-based chemotherapy. This...
Expert Point of View: Zofia Piotrowska, MD
Zofia Piotrowska, MD, of the Massachusetts General Hospital/Harvard Medical School, Boston, noted that MARIPOSA and MARIPOSA-2 are “two well-designed, randomized phase III trials, each meeting its primary endpoints and representing important advances for patients with EGFR-mutant lung cancer.”...
Amivantamab-Based Regimens Show Anticancer Activity in EGFR-Mutated Advanced NSCLC
Widely anticipated findings from the MARIPOSA1 and MARIPOSA-22 trials were presented at the European Society for Medical Oncology (ESMO) Congress 2023, showing potentially improved outcomes with regimens incorporating the bispecific antibody amivantamab-vmjw for patients with advanced non–small...
PAPILLON: Adding Amivantamab to First-Line Chemotherapy Prolongs Progression-Free Survival in NSCLC Subset
In the phase III PAPILLON trial, the addition of the bispecific antibody amivantamab-vmjw to chemotherapy resulted in a near doubling in median progression-free survival vs chemotherapy alone in patients with untreated non–small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR)...
Urban Environmental Exposures and Incidence of Breast Cancer
Investigators have uncovered that North Carolina’s urban counties may have higher overall incidences of breast cancer than its rural counties, especially at early stages at diagnosis, according to a recent study published by Gearhart-Serna et al in Scientific Reports. These findings may serve as a...
Expert Point of View: Upal Basu Roy, PhD, MPH
Upal Basu Roy, PhD, MPH, Executive Director of Research at the LUNGevity Foundation, in Chicago, shared his thoughts with The ASCO Post on the INCREASE trial’s findings and their potential impact on clinical practice. As Dr. Roy explained, neoadjuvant chemoimmunotherapy remains the current standard ...
Expert Point of View: Roy S. Herbst, MD, PhD
Roy S. Herbst, MD, PhD, cautioned that although FLAURA2 is a positive result, most patients will still develop drug resistance. “The result is really good and clearly positive, but if you look at the survival curves, there is still early overlap in a way that makes it unlikely this combination will ...
Expert Point of View: Gerard A. Silvestri, MD, MS
Gerard A. Silvestri, MD, MS, the Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina, Charleston, praised the investigators of the Taiwan National Lung Cancer Screening Program for their accomplishment. “It’s incredible that they screened almost 50,000...
Taiwan National Lung Cancer Early Detection Screening Program Targets Smokers and Nonsmokers With Family History
Findings from the Taiwan National Lung Cancer Early Detection Program have shown that lung cancer screening by low-dose computed tomography (CT) can detect tumors at an early-enough phase to allow for effective intervention. In a recent analysis, 85% of tumors detected by screening were stage 0 or...
Extended Pleurectomy Decortication Plus Chemotherapy for Mesothelioma Linked to Increased Risk of Death in MARS-2 Trial
The results of a recent study from the United Kingdom could spell the end of a long-standing treatment strategy for mesothelioma, according to data presented during the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer.1 When combined with...
Highlights From the 2023 World Conference on Lung Cancer
The management of lung cancer and other thoracic malignancies has evolved significantly over the past decade. Thanks to many scientific advancements in the field, new therapeutic options, and improvements in screening and early detection, more patients are being cured, and many others are living...
A Cancer Diagnosis at 19 Taught Me That It Takes Constant Vigilance to Stay Mentally Healthy
A lot of my experience with cancer is hazy to me. I was taking narcotics for pain around the clock when I was diagnosed with Ewing’s sarcoma in 2013, so there are some missing memories during those early days. I was 19 and a freshman in college when my symptoms started. I have always been active in ...
From a Small Town in the Rust Belt, Dennis J. Slamon, MD, PhD, Plays a Big Role in Changing the Face of Breast Cancer Treatment
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Dennis J. Slamon, MD, PhD, one of the principals in the discovery and development of trastuzumab—the first monoclonal antibody used against an oncogene that altered our entire approach...
Cardiac Imaging and Biomarkers for Patients Receiving Cancer Treatment: What Oncologists Need to Know
For many years, researchers around the world have been exploring the connections between cancer treatments and the heart—better known as cardio-oncology. However, many oncologists may be less familiar with this emerging field and what they might need to know in terms of heart health to keep their...
Updates in Lower-Risk Myelodysplastic Syndromes/Neoplasms
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell disorders that are characterized by ineffective hematopoiesis, resulting in cytopenias, and they carry a risk of progression to acute myeloid leukemia (AML). In 2022, the fifth edition of the World Health ...
Optimizing Treatment Selection for Newly Diagnosed and Secondary AML: Focus on Cytogenetic and Molecular Data
Greater understanding of biological disease factors in acute myeloid leukemia (AML) has led to more effective and personalized treatment options. At the 2023 National Comprehensive Cancer Network (NCCN) Annual Congress: Hematologic Malignancies,1 Rebecca Olin, MD, MSCE, of UCSF Helen Diller Family...
Jarushka Naidoo, MHS, MBBCh, on Lung Cancer: Practice-Changing Advances Reported at ESMO 2023
Jarushka Naidoo, MHS, MBBCh, of the Royal College of Surgeons in Ireland, University of Medicine and Health Sciences, discusses some of the key lung cancer data presented at the ESMO Congress 2023: CheckMate 77T, a phase III study of nivolumab, chemotherapy, and surgery for previously untreated...
Early-Stage Cervical Cancer: Defining Follow-up After Fertility-Sparing Surgery
In a Dutch retrospective cohort study reported in The Lancet Oncology, Schuurman et al identified follow-up strategies based on cytology and human papillomavirus (HPV) testing after fertility-sparing surgery for early-stage cervical cancer. Study Details The nationwide population-based study used...
ASCO Rapid Recommendation Update Cautions Against Triplet Therapy for Metastatic Clear Cell RCC
An ASCO Rapid Recommendation Update advises oncologists to avoid the use of triple combination therapy for the management of metastatic clear cell renal cell carcinoma (RCC).1 The new guidance, which updates recommendations from the original 2022 guideline, reflects findings from a phase III,...
Survivors of Childhood Cancer: Study Shows Heart-Related Ailments Linked to Radiotherapy Dose
Research on the advances in radiation modeling presented by Rebecca M. Howell, PhD, at the 2023 American Society for Radiation Oncology (ASTRO) Annual Meeting may provide insights into the late cardiac effects of survivors of childhood cancer in the Childhood Cancer Survivor Study (CCSS).1 Dr....
Expert Point of View: Solange Peters, MD, PhD and Upal Basu Roy, PhD, MPH
Commenting on the AEGEAN study at the 2023 World Conference on Lung Cancer were the abstract’s invited discussant Solange Peters, MD, PhD, Professor and Chair of Medical Oncology and the Thoracic Malignancies Program at Lausanne University Hospital in Switzerland, and Upal Basu Roy, PhD, MPH,...
Prevalence of Unsatisfactory Samples From FIT Tests for Colorectal Cancer Screening
A retrospective cohort study by Liu et al published in Cancer Epidemiology, Biomarkers & Prevention investigated the prevalence and reasons for an unsatisfactory fecal immunochemical test (FIT). Researchers found that over 10% of the tests used for routine colorectal cancer screening contained...
Expert Point of View: Krishnansu Tewari, MD
The invited discussant Krishnansu Tewari, MD, Professor in the Division of Gynecologic Oncology at the University of California, Irvine, called innovaTV 301 a “practice-changing study” that should result in full approval of tisotumab vedotin-tftv in the United States “and, importantly, will...
Early Breast Cancer: Effect of Radiotherapy to Regional Nodes
As reported in The Lancet by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), an individual patient meta-analysis has shown that more recent—but not older—trials of regional lymph node radiotherapy vs no radiotherapy in patients with early breast cancer showed benefits of...
AACR Annual Cancer Progress Report Highlights Scientific Advances Against Cancer, Challenges and Opportunities Ahead
The remarkable progress in medical research—primarily supported by federal investments in the National Institutes of Health (NIH) and the National Cancer Institute (NCI)—over the past 3 decades, coupled with advances in prevention and early detection, has led to a 33% reduction in cancer...
DUO-E Trial: Durvalumab-Based Treatment With or Without Olaparib Boosts Progression-Free Survival in Endometrial Cancer
In the phase III DUO-E trial, a first-line treatment regimen that includes chemotherapy plus the checkpoint inhibitor durvalumab followed by maintenance durvalumab, with or without the PARP inhibitor olaparib, significantly improved progression-free survival in patients with advanced or recurrent...
Partial-Breast Irradiation in Patients With Early-Stage Invasive Breast Cancer or DCIS
The American Society for Radiation Oncology (ASTRO) issued recommendations for patient-centered strategies for performing partial-breast irradiation in patients with early-stage invasive breast cancer or ductal carcinoma in situ (DCIS). The new clinical guidelines were published by Shaitelman et al ...
Two Studies Show Improved Survival With Novel Front-Line Combinations in Advanced Urothelial Carcinoma
Two phase III trials presented at a Presidential Symposium during the European Society for Medical Oncology (ESMO) Congress 2023 showed an overall survival benefit for patients with advanced urothelial cancer. The results from both studies were hailed as practice-changing. The EV-302/KEYNOTE-A39...
Occupational Exposure to Solar UV Radiation and Nonmelanoma Skin Cancer
Individuals who experience occupational exposure to solar ultraviolet (UV) radiation may have a high rate of nonmelanoma skin cancer incidence and mortality, according to a recent study published by Pega et al in Environment International. These findings highlighted the large and increasing burden...
Number of Cancer Treatments Performed During Early COVID-19 Pandemic
Investigators have uncovered that fewer surgical, chemotherapy, and radiation treatments may have been performed in patients with cancer during the first months of the COVID-19 pandemic, according to a recent study published by Nogueira et al in JAMA Oncology. The new findings may be attributable...
Racial Disparities in Guideline-Concordant Care in Early-Onset Colorectal Cancer in the United States
In a study reported in the Journal of Clinical Oncology, Nogueira et al found that among U.S. Black and White patients with early-onset colorectal cancer, Black patients were more likely to receive poorer and less timely care. As stated by the investigators: “Young individuals racialized as Black...
Researchers Identify Novel Genetic Variants Predictive of Prostate Cancer Risk and Severity
Researchers have compiled a comprehensive list of genetic variants that may be associated with the risk of developing prostate cancer, according to a recent study published by Wang et al in Nature Genetics. The new findings included major increases in representation among patients from racial and...
Exposure to CT Radiation and Risk of Blood Cancers in Young Patients
Investigators may have uncovered an association between exposure to computed tomography (CT) radiation in young patients and an increased risk of hematologic malignancies, according to a recent study published by Bosch de Basea Gomez et al in Nature Medicine. These recent findings highlighted the...
Cancer Care Disparities Among Patients With Early-Onset Colorectal Cancer
Investigators have found that Black patients with early-onset colorectal cancer in the United States may receive worse and less timely, guideline-concordant care than White patients, according to a recent study published by Nogueira et al in the Journal of Clinical Oncology. Background “Colorectal...
Investigational Dual PD-1 and TIGIT Blockade in Advanced Gastroesophageal Cancer
Early findings from the phase II EDGE-Gastric trial indicate the potential for two novel agents to make a difference in advanced gastroesophageal adenocarcinoma, according to findings reported at the ASCO Plenary Series: November 2023 Session by Yelena Y. Janjigian, MD, Chief of the...
Patients With Lower-Extremity Lymphedema May Face Increased Risk of Skin Cancer
The risk of developing skin cancer may be twofold for patients with lymphedema, according to a recent study published by Anand et al in Mayo Clinic Proceedings. The new findings may contribute to growing information linking lymphedema to localized changes in immunity and a predisposition for...
Vitamin D Supplements May Help Reduce Chemotherapy-Induced Peripheral Neuropathy
Investigators have found that patients with breast cancer who have insufficient levels of vitamin D prior to initiating treatment with paclitaxel may be more likely to experience peripheral neuropathy, according to a recent study published by Chen et al in JNCCN–Journal of the National...
FDA Approves First Treatment for Patients With Rare Congenital Blood Disorder
On November 9, the U.S. Food and Drug Administration (FDA) approved ADAMTS13, recombinant-krhn (Adzynma), the first genetically engineered protein product indicated for prophylactic or on-demand enzyme replacement therapy in adult and pediatric patients with congenital thrombotic thrombocytopenic...
Advancing Clinical Research on Ovarian Cancer and Overcoming Gender Inequity in Low- and Middle-Income Countries
The management of ovarian cancer remains challenging within health-care systems worldwide. Recently, clinical and translational research on ovarian cancer has led to promising advances that have improved the survival outcomes of women diagnosed with this aggressive gynecologic cancer. These...
Screening for Lung Cancer: Much Work Remains to Be Done
Remarkable progress has been made in the treatment of lung cancer in the past 10 to 15 years; it is therefore not surprising that lung cancer mortality in the United States is declining consistently, at the rate of 2% to 4% annually in recent years. Long-term survival is possible even for patients...
How ASCO Is Tackling the Need to Improve Workforce Diversity and the Looming Oncology Workforce Shortage
On June 29, 2023, the U.S. Supreme Court, in a 6-to-3 decision, essentially overturned affirmative action in college admissions, which had allowed, since 1978, for colleges and universities to consider race as a factor in student admissions.1 The ruling will impact enrollment decisions at public...
Results of PACIFIC Trial Being Replicated in Real-World Settings
Real-world outcomes often fall short of those achieved in clinical trials, but this is apparently not so for patients receiving chemoradiotherapy plus consolidation with durvalumab in unresectable stage III non–small cell lung cancer (NSCLC). The robust results achieved in the phase III PACIFIC...
Having Colorectal Cancer at 32 Changed the Trajectory of My Life
I’ve been contending with health issues since I was 12, when I was diagnosed with Crohn’s disease. As I began my early 30s, I was feeling the healthiest of my life. I was working out 5 days a week and attributed sudden weight loss and fatigue to weight training and high-intensity Zumba classes....
Understanding Patient Engagement in Virtual Mind-Body Therapies
Guest Editor’s Note: Virtual platforms have grown increasingly popular for health- and wellness-promoting activities. But given patients’ unique backgrounds, capabilities, interests, and goals, promoting engagement represents a complex challenge both in the context of care delivery as well as...
Genetics of Nearby Healthy Tissue May Help Predict Lung Cancer Recurrence
Genetic information collected from healthy tissue near lung tumors may be predictive of posttreatment cancer recurrence compared with analysis of the tumors themselves, according to a novel study published by Dolgalev et al in Nature Communications. Background Lung adenocarcinomas are tumors that...
Nadia Harbeck, MD, PhD, on High-Risk Early Breast Cancer: Overall Survival Data on Abemaciclib Plus Endocrine Therapy
Nadia Harbeck, MD, PhD, of Munich’s LMU University Hospital and the Ludwig Maximilian University, discusses an interim analysis of the monarchE trial on adjuvant abemaciclib plus endocrine therapy for patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer. The data...
Low-Dose CT Screenings Leading to Early Diagnosis May Improve Long-Term Lung Cancer Survival Rates
Diagnosing early-stage lung cancer with low-dose computed tomography (CT) screening may improve 20-year survival rates, according to a recent study published by Henschke et al in Radiology. The new findings demonstrated the significance of routine early screenings to detect tumors when they are...
Peter Schmid, MD, PhD, on Triple-Negative Breast Cancer: Updated Results on Pembrolizumab Plus Chemotherapy
Peter Schmid, MD, PhD, of Queen Mary University of London, discusses phase III findings from the KEYNOTE-522 study, which showed neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab continues to improve event-free survival compared with neoadjuvant chemotherapy alone in...
Can High BMI in Youth Affect Cancer Risk Later On?
Men with overweight or obesity at age 18 years may have a higher risk of 17 different cancers later in life, according to recent research from the University of Gothenburg. The findings also describe how the youth obesity epidemic is expected to affect cancer incidence over the next 30 years. In...
Adding HIPEC to Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases
As reported in the Journal of Clinical Oncology by Rau et al, the German phase III GASTRIPEC-I trial showed no improvement in overall survival with the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to cytoreductive surgery in patients with gastric cancer and synchronous peritoneal...
